Apnimed, Inc.

Apnimed, Inc. ने 8 सितंबर 2026 को क्या बताया

कंपनी की अपनी 8-K रिपोर्ट से।

अर्निंग कॉल

Apnimed, Inc. के लिए कोई अर्निंग कॉल ट्रांसक्रिप्ट उपलब्ध नहीं है।

प्रबंधन ने क्या कहा

“This was a highly productive quarter for Apnimed as we continued to execute against our strategy, highlighted by the FDA’s acceptance of our NDA for AD109 (proposed proprietary name Oxnimbi), with a PDUFA target action date of February 28, 2027,”

विज्ञप्ति से हूबहू उद्धृत, और तभी दिखाया गया जब रिपोर्ट उसे किसी नामित व्यक्ति से जोड़ती है।

शेयर भाव ने कैसी प्रतिक्रिया दी

विज्ञप्तियाँ बंद होने के बाद या खुलने से पहले आती हैं, इसलिए यह हलचल अगले सत्र की है।

Apnimed, Inc. क्या करती है

Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that people with OSA would benefit from having multiple treatment options with differing mechanisms to more fully address the heterogeneity of OSA’s disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention and expand the reach of diagnosis and treatment. Apnimed is advancing its product candidate, AD109 (proposed proprietary name Oxnimbi), which is designed to improve oxygenation in individuals living with OSA. We believe that Oxnimbi could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to devices or invasive surgeries. Learn more at apnimed.com or follow us on X and LinkedIn.

कंपनी का अपना विवरण, जैसा विज्ञप्ति के अंत में दिया गया है।